학술논문
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
Document Type
article
Author
Source
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Subject
Language
English
ISSN
2041-1723
Abstract
The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is required for the response to Trastuzumab.